Bayer's August Agenda: A Profit Turnaround, a $7.25 Billion Legal Verdict, and a Debt Cure All Collide

Bayer faces pivotal weeks with half-year results, a Missouri glyphosate settlement hearing, and a €3B Apollo deal. Stock up 24% YTD but flat near €46.

Three pivotal events are converging on Bayer’s calendar in a span of just a few weeks, leaving the stock in a holding pattern as investors await clarity on the company’s turnaround. The shares closed Friday at €46.01, shedding 0.35% on the day and logging a weekly decline of 4.48%. Despite that near-term softness, the stock has still surged 24.32% since the start of the year, making it one of the DAX’s top performers in 2026.

Earnings Signal a Swing Back to Profit

The first major catalyst arrives on August 4, when Bayer publishes its half-year results. Analysts are penciling in earnings per share of €0.769 for the second quarter, a stark reversal from the €0.200 loss per share recorded in the same period last year. Revenue is expected to come in at roughly €10.73 billion.

The company entered a quiet period on July 15, so no operational updates have leaked since then. The spotlight will fall squarely on the Crop Science division, where investors are desperate to know whether the agricultural business has finally bottomed out on pricing. The answer will likely shape Bayer’s full-year outlook.

The Missouri Hearing That Could Close a Chapter

Just two weeks after the numbers, on August 19, a court in Missouri will hold a fairness hearing to grant final approval to Bayer’s $7.25 billion glyphosate class-action settlement. The hearing was originally scheduled for early July but was postponed.

Bayer enters this courtroom with renewed confidence. In late June, the U.S. Supreme Court ruled 7-2 in the Durnell case that federal labeling requirements for herbicides preempt state-level warning obligations—a clear win for the company. A positive outcome on August 19 would resolve a substantial portion of the legal overhang that has weighed on the stock for years, effectively removing one of the biggest clouds from Bayer’s balance sheet.

Apollo Deal Fuels the Debt-Reduction Engine

While the legal and operational dramas play out, CEO Bill Anderson is pushing ahead with a deleveraging strategy. On July 10, Bayer announced a deal with Apollo Global Management: the private equity firm will take a minority stake in a newly created entity that holds Bayer’s long-acting reversible contraceptive (LARC) business. The transaction injects €3.0 billion in equity into Bayer, which retains majority control and full operational oversight of the unit.

The deal is expected to close in the third quarter of 2026. The fresh capital will bolster Bayer’s financial flexibility as it faces upcoming bond maturities, and it also frees up resources to handle the remaining litigation costs.

Analyst Opinions Diverge on the Path Ahead

Wall Street is split on Bayer’s prospects. Jefferies has kept its price target at €46.00, arguing that portfolio moves like the Apollo deal are necessary but not sufficient for a re-rating. Barclays and J.P. Morgan are more bullish, setting targets of €60.00 and €50.00 respectively, both pointing to the Supreme Court ruling as a game-changer that reduces legal risk.

Technicals Point to a Neutral Staging Ground

On the charts, the stock is finding support at its 50-day moving average of €42.14. The Relative Strength Index sits at 49.6, squarely in neutral territory after a brief overbought spell in early July. That leaves plenty of room for a breakout—or a breakdown—once the August catalysts land.

Three events, one month, and a stock that has already climbed a quarter of the way this year. Whether that rally holds depends on whether Bayer can deliver a clean sweep: a profit turnaround on August 4, a legal clearance on August 19, and a closed Apollo deal shortly after.